Search
ABVC Biopharma Inc
ABVCAdd to Watchlist
1.800USD
+0.030+1.69%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
46.38MMarket Cap
LossP/E TTM
More Details of ABVC Biopharma Inc Company
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.
ABVC Biopharma Inc Info
Ticker SymbolABVC
Company nameABVC Biopharma Inc
IPO dateNov 09, 2004
CEOPatil (Uttam Yashwant)
Number of employees16
Security typeOrdinary Share
Fiscal year-endNov 09
Address44370 Old Warm Springs Blvd
CityFREMONT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94538-6148
Phone15106680881
Websitehttps://abvcpharma.com/
Ticker SymbolABVC
IPO dateNov 09, 2004
CEOPatil (Uttam Yashwant)
Company Executives of ABVC Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Shuling Jiang
Ms. Shuling Jiang
Director
Director
3.07M
--
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Chief Scientific Officer, Chief Strategy Officer, Director
Chief Scientific Officer, Chief Strategy Officer, Director
375.99K
--
Mr. Eugene Jiang
Mr. Eugene Jiang
Chairman of the Board, Chief Business Officer
Chairman of the Board, Chief Business Officer
126.64K
--
Mr. Yoshinobu Odaira
Mr. Yoshinobu Odaira
Independent Director
Independent Director
57.76K
--
Dr. Tsang Ming Jiang, Ph.D.
Dr. Tsang Ming Jiang, Ph.D.
Director
Director
41.99K
--
Ms. Yen-Hsin Chou
Ms. Yen-Hsin Chou
Independent Director
Independent Director
41.96K
--
Dr. Chang-Jen Jiang, M.D.
Dr. Chang-Jen Jiang, M.D.
Director
Director
41.95K
-0.00%
Ms. Norimi Sakamoto
Ms. Norimi Sakamoto
Independent Director
Independent Director
41.85K
--
Ms. Hsin-Hui Miao
Ms. Hsin-Hui Miao
Independent Director
Independent Director
41.51K
--
Mr. Yu- Min (Francis) Chung
Mr. Yu- Min (Francis) Chung
Independent Director
Independent Director
41.39K
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Shuling Jiang
Ms. Shuling Jiang
Director
Director
3.07M
--
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Chief Scientific Officer, Chief Strategy Officer, Director
Chief Scientific Officer, Chief Strategy Officer, Director
375.99K
--
Mr. Eugene Jiang
Mr. Eugene Jiang
Chairman of the Board, Chief Business Officer
Chairman of the Board, Chief Business Officer
126.64K
--
Mr. Yoshinobu Odaira
Mr. Yoshinobu Odaira
Independent Director
Independent Director
57.76K
--
Dr. Tsang Ming Jiang, Ph.D.
Dr. Tsang Ming Jiang, Ph.D.
Director
Director
41.99K
--
Ms. Yen-Hsin Chou
Ms. Yen-Hsin Chou
Independent Director
Independent Director
41.96K
--
FAQs
Who are the top five shareholders of ABVC Biopharma Inc?
The top five shareholders of ABVC Biopharma Inc are: Ms. Shuling Jiang
How many institutions hold shares of ABVC Biopharma Inc (ABVC)?
As of 2026Q1, 27 institutions hold shares of ABVC Biopharma Inc, with a combined market value of approximately 866.42K, accounting for 3.41% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -376527.00.